This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hande, K. Articles by Branch, R. Search for Related Content PubMed PubMed Citation Articles by Hande, K. Articles by Branch, R.

Metabolism and Excretion of Etoposide in Isolated, Perfused Rat Liver Models

Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, and the Nashville Veterans Administration Medical Center, Nashville, Tennessee 37232

The clearance of etoposide and formation of etoposide glucuronide have been measured in an isolated, perfused rat liver model to evaluate the effect of impaired hepatic function on etoposide kinetics. Hepatocellular injury was produced by pretreatment of rats with allyl alcohol or carbon tetrachloride; ligation of the bile duct simulated obstructive biliary disease. Etoposide clearance (3.59 ± 1.06 ml/min) was reduced by both carbon tetrachloride (2.07 ± 0.64 ml/min; P = 0.05) and allyl alcohol treatment (2.14 ± 0.62 ml/min; P = 0.05). Biliary obstruction also impaired etoposide clearance but to a lesser extent than hepatocellular injury (2.47 ± 0.69 ml/min; P = 0.20 versus control). In both hepatocellular and obstructive models, direct biliary etoposide excretion decreased. The metabolic clearance of etoposide to its glucuronide declined by 36% in the hepatotoxin models but was not decreased by biliary obstruction.

Following hepatic injury, there is a reduction in the metabolism and excretion of etoposide by the liver. This effect is most marked on biliary drug excretion. Obstructive biliary disease does not significantly alter etoposide glucuronidation. Since most cancer patients have increased bilirubin on the basis of obstructive disease, little or no etoposide dose alteration will be needed. However, in the patient with significant hepatocellular injury, impaired etoposide clearance will be more pronounced, and etoposide dose alterations may be needed.

¹ To whom requests for reprints should be addressed, at 1956 The Vanderbilt Clinic, Nashville, TN 37232.

² Supported by NIH Grant CA 39686 and by the Veterans Administration.

Received 1/15/88. Revised 7/ 6/88. Accepted 7/15/88.

This article has been cited by other articles:

				Z. Wen, M. N. Tallman, S. Y. Ali, and P. C. Smith UDP-Glucuronosyltransferase 1A1 Is the Principal Enzyme Responsible for Etoposide Glucuronidation in Human Liver and Intestinal Microsomes: Structural Characterization of Phenolic and Alcoholic Glucuronides of Etoposide and Estimation of Enzyme Kinetics Drug Metab. Dispos., March 1, 2007; 35(3): 371 - 380. [Abstract] [Full Text] [PDF]

				D. E. Burgio, M. P. Gosl, and a. P. J. McNamara Effects of P-glycoprotein Modulators on Etoposide Elimination and Central Nervous System Distribution J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 911 - 917. [Abstract] [Full Text]